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Review Article
Depression and anxiety in obstructive sleep
apnea syndrome: a review
Introduction
Obstructive sleep apnea syndrome (OSAS) is the
most common type of sleep apnea. It is characterized
by repetitive complete (apnea) and partial (hypop-
nea) obstruction of the upper airway during sleep
and results in oxygen desaturation and arousals
from sleep (1). Up to 4% of men and 2% of women
have clinically important sleep apnea (2). The
severity of OSAS varies. The frequency of respirat-
ory breathing events during sleep correlates poorly
with the severity of daytime symptoms (1). Themost
common treatment for OSAS is continuous positive
airway pressure (CPAP) (3), which improves oxygen
saturation and reduces sleep fragmentation.
Depression has been reported to be the most
common mood disorder associated with OSAS
(4–7), although not all studies have found a
correlation (4–6, 8). It is unclear if depression in
OSAS is a primary consequence or if it occurs
secondary to OSAS-related symptoms (sleepiness,
sleep problems, irritability, social withdrawal) or to
other factors related to OSAS (e.g., obesity,
hypertension) (4–7). Because of the complex rela-
tionship between OSAS and depression, the cur-
rent recommendation is that a mood disorder
should be considered as secondary to the medical
disorder and not as a distinct psychiatric entity
(4, 7). This should also be applied the other way
round: if the patient suffers from depression,
fatigue, and sleeping problems, the ﬁrst step is to
establish whether OSAS lies behind these symp-
toms (9). Earlier reviews also draw a link between
anxiety and OSAS (5–7, 10), but the evidence is far
from conclusive (5). The severity of depression and
anxiety seem to correlate more with excessive
daytime sleepiness than with hypoxemia (6, 7).
Speciﬁc attention should be paid to the evaluation
of mood disorders in OSAS, because some of the
methods used may in fact reﬂect sleep quality and
daytime sleepiness rather than mood state (5, 10,
11). The most commonly used mood scales for
assessing depression and anxiety are presented in
Table 1. The view that depression in OSAS can be
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explained by common symptoms is also supported
by the positive impacts of CPAP treatment on the
depressive state (5, 7). The treatment of OSAS may
also reveal, if there exists a primary depressive
disorder and if the focus of treatment should be
turned on that (9). There are no earlier reports of
CPAP having clear effect on anxiety.
There are only a few earlier reviews on OSAS and
mood alterations, and none of these are systematic
(4–8). Our review offers an update on recent
research ﬁndings over the past 10 years (from
January 1995 to June 2006) with respect to the
most common mood alterations in OSAS, namely
depression and anxiety. Our focus is on the preval-
ence of depression and anxiety, and on how mood
has been examined in OSAS. In particular, we
address the following questions: (i) what generali-
zations can be drawn fromprevious studies based on
the number, age and gender of the subjects, and the
severity of OSAS; (ii) what methods have been used
to assess mood; (iii) what is the prevalence of
depression and anxiety in OSAS; and (iv) does
CPAP treatment have a long-term effect on mood?
Materials and methods
Main terms used in the search
Obstructive sleep apnea syndrome is described in
the literature by a variety of concepts: obstructive
sleep apnea, obstructive sleep apnea syndrome,
obstructive sleep apnea-hypopnea syndrome, sleep
apnea-hypopnea syndrome, and obstructive sleep-
disordered breathing. Because the term obstructive
sleep apnea seems to appear most frequently, this
is what we used in our search. To identify speciﬁc
aspects of mood, the terms depression and anxi-
ety were used.
Selection of the articles
We began by searching the Cochrane Library
database to see whether there were any recent or
ongoing reviews on this subject, but we found
none. We then searched MEDLINE and PSYCH-
LIT for articles published between January 1995
and June 2006 using the terms obstructive sleep
apnea and depression and obstructive sleep apnea
and anxiety. We found a total of 203 articles.
Following the exclusion of non-English articles,
and studies of non-human subjects, we had 149
remaining articles. Next, we excluded case reports,
reviews, experimental studies, letters, commentar-
ies, abstracts, and chapters of edited volumes. This
left us with 100 articles. The abstracts of these
articles were reviewed.
As we were speciﬁcally interested in adult OSAS
patients and mood alterations, and in the impact of
CPAP treatment on mood alterations, we imposed
the following exclusion criteria: (i) studies inclu-
ding children and ⁄or adolescents, deﬁned as par-
ticipants under 18 years of age (10 articles were
excluded); (ii) studies focusing on medical eﬀects
(11 articles were excluded); (iii) studies including
special medical populations only (e.g., dementias,
insomnias, asthma) or in addition to OSAS (14
articles were excluded); (iv) studies in which OSAS
was not veriﬁed by polysomnography or OSAS
was not a diagnostic criterion (eight articles were
excluded); (v) studies not including an evaluation
of mood or not reporting the results of mood
assessment methods in OSAS (15 articles were
excluded); and (vi) studies not including patient
data (one article was excluded). We now had 41
articles which were fully reviewed. The lists of
references of these studies were searched; this
yielded 14 additional articles for our review. The
total number of articles reviewed for this study was
thus 55 articles.
Results
A selected group of patients was recruited in 34 out
of 55 studies (21–54). In 21 studies (55–75) the
patient sample was drawn from consecutive series.
The number of patients ranged from 8 to 1635
(median: 54). The mean age of patients ranged from
44 to 69 years (median: 49 years). Eight studies (26,
28, 34, 38, 51, 58, 65, 71) did not report the mean
age for the patient group. The proportion of men in
the study samples ranged from 13% to 100%
(median: 83%). In 10 studies (26–28, 39, 46, 51, 58,
63, 65, 71) the gender breakdown was not speciﬁed
for the OSAS patient group. The severity of sleep
apnea was mostly reported using the respiratory
disturbance index or the apnea hypopnea index
(AHI), indicating the frequency of apneas and
hypopneas per hour of sleep. The mean severity of
OSAS ranged from 10 to 99 apneas and hypopneas
per hour (median: 48 apneas and hypopneas per
hour), and the standard deviations varied widely.
One study (42) reported the range and the median
of AHI, one study (59) speciﬁed severity using the
desaturation index indicating ‡4% decrease in
minimum oxygen saturation at least ﬁve times per
hour or at least 30 saturations during 7 h sleep, and
one study (31) using the apnea index indicating the
frequency of apneas per hour of sleep and apneic
episodes per night. In two studies (34, 58) severity
was reported categorically (mild, moderate, severe)
without specifying the mean number of apneas and
hypopneas per hour. In four studies (51, 65, 68, 71)
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the severity of sleep apnea was not reported for the
OSAS group.
Assessment of mood
The scales used most often to assess mood in OSAS
patients are presented in Table 2. Different versions
of the Beck Depression Inventory (BDI) were
applied and one study (61) used the Beck question-
naires (76) including both evaluations of both
depression and anxiety. It remained unclear if one
study (31) also used a Japanese version of Zung
SDS (77). Three studies (39, 49, 59) used the
Structured Clinical Interview for DSM-IV (78),
DSM-III-R (79) or DSM-III (80). In six studies
(25–28, 66, 70) the patients were interviewed by a
psychiatrist, and in one study (36) an interview on
psychological wellbeing was conducted without
specifying the protocol. History of depression was
assessed retrospectively in one study (25) to identify
any diagnoses the OSAS patients might have before
the diagnosis of sleep apnea, and one study (54)
used medical history, medication usage and a
general questionnaire. Depressive state was also
diagnosed on the basis of self-reported symptoms
(68) and discourse analysis (42). The following
Table 1 Overview of the mood scales most commonly used in assessing depression and anxiety in obstructive sleep apnea syndrome
Mood scale Description of the scale
Beck Depression Inventory (BDI; 12) A 21-item scale consisting of statements focusing on particular aspects of depression-related
symptoms (e.g., mood, sense of failure, appetite, sleeping). The subject rates the intensity
of the items on a 4-point scale (0–3). The total score ranges from 0 to 63
Zung Self-Rating Depression Scale (Zung SDS; 13) A 20-item questionnaire in which scores can be interpreted in four symptom groups: affect,
physiological disturbances, psychomotor disturbance, psychological disturbance, and additionally
overall self-rated depression. The subject rates the appearance of symptoms using a 4-point
scale (1–4) and the items are balanced for yes ⁄ no tendencies. The total raw score ranges
from 20 to 80; the final score is often reported by multiplying raw scores by 1.25 to yield
results between 25 and 100
Center for Epidemiological Studies
Depression Scale (CES-D; 14)
A 20-item self-report questionnaire taps cognitive ⁄ affective aspects of depression in seven components:
depressed mood, feelings of guilt, helplessness, worthlessness, loss of appetite, psychomotor retardation,
and sleep disturbance. The subject rates the appearance of mood-related aspects on a 4-point
scale (0–3). The total score ranges from 0 to 60
Hospital Anxiety and Depression Scale (HADS; 15) A 14-item scale which consists of seven items assessing anhedonic state associated with depression,
and seven items focusing on psychic manifestations of anxiety neurosis. It is developed to detect
depression and anxiety free from somatic referents. The subject rates the items on a 4-point
scale (0–3). The total scores on both subscales range from 0 to 21
State-Trait Anxiety Inventory (STAI; 16) A 40-item scale including two subscales: state anxiety and trait anxiety. Both subscales consist of
20 items and the subject rates his feelings on a 4-point intensity scale and on a 4-point
frequency scale (1–4). The total scores on both subscales range from 20 to 80
Profile of Mood States (POMS; 17) A 65-item adjective rating scale on six subscales: fatigue-inertia, depression-dejection, vigor-activity,
anger-hostility, tension-anxiety and confusion-bewilderment. The subject rates the items
on a 5-point scale (0–4)
Minnesota Multiphasic Personality Inventory (MMPI; 18, 19) A 550-item personality test spanning a broad variety of psychiatric symptoms, personality features,
and psychological difficulties on 10 subscales: hypochondriasis, depression, hysteria, psychopathic
deviate, masculinity ⁄ femininity, paranoia, psychasthenia, schizophrenia, hypomania, and social
introversion. The subject rates the items on true ⁄ false responses
Symptom Distress Check List (SCL-90; 20) A 90-item scale is used to evaluate self-reported behavioral and psychiatric distress on nine
subscales: somatization, obsessive-compulsive, interpersonal sensitivity, depression, anxiety,
hostility, phobic anxiety, paranoid ideation, psychoticism, and general severity index. The subject
rates the occurrence and intensity of distress symptoms on a 5-point scale (0–4)
Table 2 Mood scales most often used in assessing depression and anxiety in obstructive sleep apnea syndrome in the studies reviewed
Mood scale No. studies using the scale
Beck Depression Inventory (BDI; 12) 19 (21, 36, 38, 44–50, 52, 53, 61, 64–66, 69, 70, 75)*
Hospital Anxiety and Depression Scale (HADS; 15) 11 (23, 30, 39, 55–57, 60, 62, 63, 73, 74)
Profile of Mood States (POMS; 17) 10 (24, 29, 32, 35, 38, 41, 43, 46, 47, 50)
Center for Epidemiological Studies Depression Scale (CES-D; 14) 6 (29, 33, 35, 41, 43, 71)
State-Trait Anxiety Inventory (STAI; 16) 4 (29, 31, 36, 41)
Zung Self-Rating Depression Scale (Zung SDS; 13) 3 (34, 37, 72)
Minnesota Multiphasic Personality Inventory (MMPI; 18, 19) 3 (25, 26, 28)
Symptom Distress Check List (SCL-90; 20) 3 (27, 58, 64)
*Numbers in parentheses refer to the original articles reviewed.
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scales were used to assess depression and ⁄or
anxiety in one or two studies each (21, 22, 29, 31,
36, 51, 67): the Hamilton Rating Scale for Anxiety
(HRSD; 81), the Hamilton Rating Scale for
Depression (HRSD; 82), the Mental Health Scale
(MH-5; 83), the Montgomery-Asperg Depression
Rating Scale (MADRS; 84), and the Taylors
Manifest Anxiety Scale (MAS; 85). Other scales
used in the studies reviewed (21, 24, 29, 31, 35, 39,
41, 59) were the Comprehensive Psychopathologi-
cal Rating Scale (CPRS; 86), the Positive and
Negative Affect Scale (PANAS; 87), the Tempera-
ment and Character Inventory (TCI; 88), the Ways
of Coping Questionnaire (WC; 89), the Buss-
Durkee Hostility Scale (BD; 90), the Cook-
Medley Hostility Scale (CM; 91), a Japanese
version of Cornell Medical Index (CMI; 92), a
Japanese version of the Yatabe-Guilford Test (Y-G
test; 93), and Tylkas Psychological Evaluation of
the Effectiveness of Rehabilitation, which is a
Polish modiﬁcation of Cattells Scale (SOPER; 94).
Pretreatment depression and anxiety in OSAS
The results on the prevalence of depression and ⁄or
anxiety and the respective assessment methods
used in the studies reviewed are listed in Table 3.
Prevalences are only reported when directly avail-
able from the original study or when they could be
calculated from the results. Figures for the preval-
ence of depression were available from 24 studies
(21, 25–28, 31, 33–35, 37–40, 43, 45, 47, 54, 59, 62,
65, 68, 69, 73, 75) and ﬁgures for the prevalence of
anxiety from seven studies (21, 27, 30, 31, 39, 62,
73). The prevalence of depression ranged from 7%
to 63%. Where the intensity of depressive symp-
toms was reported, most of the patients had mild
depression (31, 45, 59, 65, 69). The prevalence of
anxiety ranged from 11% to 70%.
Impact of CPAP treatment on depression and anxiety in OSAS
Twenty-seven of the ﬁfty-ﬁve studies reviewed
(49%) included evaluations of some aspects of
mood and CPAP treatment (21–24, 30, 32, 34, 36,
38, 41, 42, 45, 47–49, 55, 56, 60–64, 70, 72–75). Two
of the CPAP studies did not include post-treatment
measurements, but one of these studies (42) repor-
ted the effects of CPAP treatment on quality of life,
and the other (73) assessed how anxiety and
depression are related to CPAP use based on self-
report questionnaires completed by patients. In 25
studies (21–24, 30, 32, 34, 36, 38, 41, 45, 47–49, 55,
56, 60–64, 70, 72, 74, 75) including post-treatment
measurements after CPAP, treatment time ranged
from 1 week to 2 years (median: 8 weeks). Twenty
of these studies (23, 24, 30, 32, 34, 38, 41, 45, 47–49,
55, 58, 62–64, 70, 72, 74, 75) conducted one follow-
up, and ﬁve studies (21, 22, 36, 56, 61) conducted
two follow-ups. In the studies (22–24, 30, 32, 36, 38,
41, 45, 47, 55, 56, 60–63, 74) that reported objective
compliance with CPAP therapy, compliance ranged
from 3.1 to 7.0 h per night (median: 5.2 h). One
study reported the overall compliance results in
percent (34). Three studies (70, 72, 75) reported the
minimum demanded using hours per night and ⁄or
the minimum using nights per week. Four studies
(21, 48, 49, 64) did not specify compliance. Seven
studies (23, 30, 32, 38, 47, 55, 74) were placebo-
controlled, and one study (24) had a control group
of OSAS patients receiving conservative treatment.
Five studies (22, 41, 49, 56, 63) did not report the
effects of CPAP treatment on mood alterations. Of
these ﬁve studies, one (49) focused on how auto-
biographical memory can predict affective disor-
ders; two (41, 63) were interested in the relationship
between mood and CPAP use; one (56) assessed
how alteration in CPAP requirement affects mood;
and one (22) focused on auditory event-related
potentials.
We concentrated on the studies with the treat-
ment time ‡3 months (21, 34, 36, 45, 47, 60, 61),
because changes in mood cannot be expected
during a short period. Only one of these studies
(47) was placebo-controlled. The effect of CPAP
treatment on depression was evaluated in all of
these seven studies and on anxiety in four (21, 36,
60, 61) out of seven studies. Depression declined in
four (34, 36, 45, 60) out of seven studies and anxiety
in two (36, 60) out of four studies. The results on the
effect of CPAP treatment on depression and
anxiety in OSAS patients are presented in Table 4.
Discussion
This review provides an update on recent research
ﬁndings over the past 10 years on depression and
anxiety in OSAS with special reference to the
following aspects: the generalizability of earlier
studies based on patient characteristics, the meth-
ods used in the assessment of depression and
anxiety, the overlap of sleepiness and mood alter-
ations, the prevalence of depression and anxiety,
and the possible long-term impact of CPAP
treatment on these mood disorders.
The number of subjects in the studies reviewed
ranged from 8 to 1635. This wide disparity in sample
size clearly undermines the comparability of the
studies. Most of the studies (62%) recruited patient
groups from selected samples, although many stud-
ies failed to describe their patient selection. Con-
secutive selection is a more reliable method for
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4
T
a
b
le
3
Pr
ev
al
en
ce
of
de
pr
es
si
on
an
d
an
xi
et
y
in
ob
st
ru
ct
iv
e
sl
ee
p
ap
ne
a
sy
nd
ro
m
e
in
th
e
st
ud
ie
s
re
vi
ew
ed
Re
fe
re
nc
e
Pa
tie
nt
ch
ar
ac
te
ris
tic
s:
(a
)N
um
be
r
of
su
bj
ec
ts
(b
)G
en
de
r
(c
)A
ge
(y
ea
rs
):
m
ea
n
(S
D)
(d
)S
ev
er
ity
of
OS
AS
:m
ea
n
(S
D)
M
oo
d
sc
al
e
(s
co
rin
g:
ra
ng
e)
Pr
ev
al
en
ce
of
de
pr
es
si
on
an
d
an
xi
et
y
Al
oi
a
et
al
.(
69
)
(a
)9
3
(b
)6
1
M
;3
2
F
(c
)5
2
(1
1)
(d
)R
DI
:4
2
(2
4)
BD
I-I
I
(ra
ng
e:
0–
63
)
24
%
of
th
e
pa
tie
nt
s
ha
d
m
ild
de
pr
es
si
on
,5
%
m
od
er
at
e
de
pr
es
si
on
,
an
d
4%
se
ve
re
de
pr
es
si
on
.B
DI
m
ea
n
sc
or
e
(S
D)
fo
r
th
e
w
ho
le
st
ud
y
gr
ou
p
w
as
11
(7
)
Kj
el
sb
er
g
et
al
.(
73
)
(a
)1
78
(b
)1
35
M
;4
3
F
(c
)5
5
(1
1)
(d
)A
HI
:2
9
(2
1)
HA
DS
(ra
ng
e:
de
pr
es
si
on
su
bs
ca
le
:
0–
21
;a
nx
ie
ty
su
bs
ca
le
:0
–2
1)
11
%
of
th
e
pa
tie
nt
s
ha
d
hi
gh
de
pr
es
si
on
an
d
11
%
ha
d
hi
gh
an
xi
et
y
HA
DS
de
pr
es
si
on
m
ea
n
sc
or
e
(S
D)
fo
r
th
e
w
ho
le
pa
tie
nt
gr
ou
p
w
as
4.
8
(4
.0
)
HA
DS
an
xi
et
y
m
ea
n
sc
or
e
(S
D)
fo
r
th
e
w
ho
le
pa
tie
nt
gr
ou
p
w
as
5.
4
(4
.4
)
Sc
hw
ar
tz
et
al
.(
75
)
(a
)5
0
(o
f
w
hi
ch
31
on
an
tid
ep
re
ss
an
t
m
ed
ic
at
io
n)
(b
)3
3
M
;1
7
F
(c
)4
8
(9
)
(d
)R
DI
:5
6
(3
4)
BD
I(
7
ite
m
s)
(ra
ng
e:
0–
21
)
50
%
of
th
e
pa
tie
nt
s
ha
d
m
ild
to
se
ve
re
de
pr
es
si
on
.B
DI
m
ea
n
sc
or
e
(S
D)
fo
r
pa
tie
nt
s
w
ith
an
tid
ep
re
ss
an
t
m
ed
ic
at
io
n
w
as
5.
6
(4
.3
)
an
d
fo
r
pa
tie
nt
s
w
ith
no
an
tid
ep
re
ss
an
t
m
ed
ic
at
io
n
3.
2
(2
.9
)
Sh
ep
er
ty
ck
y
et
al
.(
54
)
(a
)2
60
(b
)1
30
M
;1
30
F
(c
)4
8
(1
)
(d
)A
HI
:3
7
(3
)f
or
m
en
;3
6
(3
)f
or
w
om
en
Hi
st
or
y
of
de
pr
es
si
on
7%
of
m
en
an
d
21
%
of
w
om
en
ha
d
hi
st
or
y
of
de
pr
es
si
on
.
W
om
en
ha
d
di
ag
no
si
s
of
de
pr
es
si
on
m
or
e
of
te
n
an
d
w
er
e
m
or
e
lik
el
y
to
be
tre
at
ed
fo
r
de
pr
es
si
on
Ba
rn
es
et
al
.(
47
)
(a
)1
14
(b
)9
1
M
;2
3
F
(c
)4
7
(1
)
(d
)A
HI
:2
1
(1
)
BD
I
(ra
ng
e:
0–
63
)
PO
M
S*
40
%
of
pa
tie
nt
s
ha
d
de
pr
es
si
on
ba
se
d
on
BD
I.
BD
Im
ea
n
sc
or
e
(S
D)
fo
r
th
e
pa
tie
nt
gr
ou
p
w
as
9.
2
(0
.5
).
PO
M
S
to
ta
lm
ea
n
sc
or
e
(S
D)
fo
r
th
e
pa
tie
nt
gr
ou
p
w
as
15
.5
(2
.0
)
Qu
in
ta
na
-G
al
le
go
et
al
.(
68
)
(a
)1
16
6
(b
)9
70
M
;1
96
F
(c
)5
3
(1
1)
fo
r
m
en
;5
8
(1
0)
fo
r
w
om
en
(d
)R
DI
‡1
0
Se
lf-
re
po
rte
d
de
pr
es
si
on
13
%
of
m
en
an
d
36
%
of
w
om
en
re
po
rte
d
de
pr
es
si
on
W
om
en
w
ith
OS
AS
ha
d
m
or
e
de
pr
es
si
on
Ba
rd
w
el
le
t
al
.(
43
)
(a
)6
0
(b
)5
1
M
;9
F
(c
)4
9
(8
)
(d
)R
DI
:4
9
(2
7)
CE
S-
D
(ra
ng
e:
0–
60
)
PO
M
S*
33
%
of
th
e
pa
tie
nt
s
ha
d
m
oo
d
di
so
rd
er
ba
se
d
on
CE
S-
D.
CE
S-
D
m
ea
n
sc
or
e
(S
D)
fo
r
th
e
pa
tie
nt
gr
ou
p
w
as
12
.6
(1
1.
3)
.
PO
M
S
de
pr
es
si
on
m
ea
n
sc
or
e
(S
D)
fo
r
th
e
pa
tie
nt
gr
ou
p
w
as
9.
3
(1
1.
6)
Do
he
rty
et
al
.(
62
)
(a
)4
5
(b
)4
4
M
;1
F
(c
)5
1
(ra
ng
e:
44
–5
8)
(d
)A
HI
:3
2
(ra
ng
e:
21
–5
7)
HA
DS
(ra
ng
e:
de
pr
es
si
on
su
bs
ca
le
:0
–2
1;
an
xi
et
y
su
bs
ca
le
:0
–2
1)
44
%
of
th
e
pa
tie
nt
s
ex
hi
bi
te
d
de
pr
es
si
on
an
d
50
%
of
th
e
pa
tie
nt
s
ex
hi
bi
te
d
an
xi
et
y
HA
DS
de
pr
es
si
on
m
ea
n
sc
or
e
fo
r
th
e
pa
tie
nt
gr
ou
p
w
as
5
(ra
ng
e:
3–
8)
HA
DS
an
xi
et
y
de
pr
es
si
on
m
ea
n
sc
or
e
fo
r
th
e
pa
tie
nt
gr
ou
p
w
as
8
(ra
ng
e:
5–
9)
Depression and anxiety in OSAS
5
T
a
b
le
3
(C
on
tin
ue
d)
Re
fe
re
nc
e
Pa
tie
nt
ch
ar
ac
te
ris
tic
s:
(a
)N
um
be
r
of
su
bj
ec
ts
(b
)G
en
de
r
(c
)A
ge
(y
ea
rs
):
m
ea
n
(S
D)
(d
)S
ev
er
ity
of
OS
AS
:m
ea
n
(S
D)
M
oo
d
sc
al
e
(s
co
rin
g:
ra
ng
e)
Pr
ev
al
en
ce
of
de
pr
es
si
on
an
d
an
xi
et
y
M
ea
ns
et
al
.(
45
)
(a
)3
9
(b
)3
5
M
;4
F
(c
)5
8
(1
1)
(d
)R
DI
:4
7
(3
4)
BD
I
(ra
ng
e:
0–
63
)
26
%
of
pa
tie
nt
s
ha
d
m
ild
de
pr
es
si
on
,8
%
ha
d
m
od
er
at
e
de
pr
es
si
on
,a
nd
3%
ha
d
se
ve
re
de
pr
es
si
on
.B
DI
m
ea
n
sc
or
e
(S
D)
fo
r
th
e
pa
tie
nt
gr
ou
p
w
as
9.
6
(7
.6
)
Va
nd
ep
ut
te
an
d
De
W
ee
rd
(6
4)
(a
)1
67
(b
–d
no
t
re
po
rte
d)
BD
I
(ra
ng
e:
0–
63
)
41
%
of
pa
tie
nt
s
ha
d
so
m
e
fo
rm
of
de
pr
es
si
on
;
2%
of
pa
tie
nt
s
ha
d
m
od
er
at
e
to
se
ve
re
de
pr
es
si
on
.
BD
Im
ea
n
sc
or
e
(S
D)
fo
r
th
e
pa
tie
nt
gr
ou
p
w
as
10
.0
(0
.6
)
Ak
as
hi
ba
et
al
.(
37
)
(a
)6
0
(b
)5
8
M
;2
F
(c
)4
8
(1
1)
(d
)A
HI
:5
2
(2
7)
Zu
ng
SD
S
(ra
ng
e:
25
–1
00
)
48
%
of
th
e
pa
tie
nt
s
w
er
e
de
pr
es
si
ve
.
Zu
ng
SD
S
m
ea
n
sc
or
e
(S
D)
fo
r
th
e
pa
tie
nt
gr
ou
p
w
as
50
.5
(1
1.
4)
Ba
rn
es
et
al
.(
38
)
(a
)4
2
(b
)3
5
M
;7
F
(c
)m
id
dl
e-
ag
ed
(d
)A
HI
:1
3
(6
)
BD
I
(ra
ng
e:
0–
63
)
PO
M
S*
16
%
of
pa
tie
nt
s
ha
d
m
ild
to
se
ve
re
de
pr
es
si
on
ba
se
d
on
BD
I
56
%
ha
d
a
to
ta
lm
oo
d
di
so
rd
er
sc
or
e
ab
ov
e
th
e
pr
ed
ic
te
d
ra
ng
e
in
PO
M
S
Sf
or
za
et
al
.(
39
)
(a
)4
4
(b
)n
ot
re
po
rte
d
(c
)5
3
(2
)
(d
)A
HI
:4
5
(4
)
HA
DS
(ra
ng
e:
de
pr
es
si
on
su
bs
ca
le
:
0–
21
;a
nx
ie
ty
su
bs
ca
le
:0
–2
1)
St
ru
ct
ur
ed
Cl
in
ic
al
In
te
rv
ie
w
ba
se
d
on
DS
M
-II
I
7%
of
pa
tie
nt
s
ha
d
de
pr
es
si
on
an
d
16
%
of
pa
tie
nt
s
ha
d
an
xi
et
y.
HA
DS
de
pr
es
si
on
m
ea
n
sc
or
e
(S
D)
fo
r
th
e
pa
tie
nt
gr
ou
p
w
as
4.
4
(0
.6
).
HA
DS
an
xi
et
y
m
ea
n
sc
or
e
(S
D)
fo
r
th
e
pa
tie
nt
gr
ou
p
w
as
7.
0
(0
.5
)
Sm
ith
et
al
.(
40
)
(a
)7
73
(b
)5
99
M
;1
74
F
(c
)4
7
(0
.5
)f
or
m
en
;5
1
(1
)f
or
w
om
en
(d
)A
HI
:4
2
(1
)f
or
m
en
;2
8
(2
)f
or
w
om
en
Ba
se
d
on
fo
rm
er
di
ag
no
si
s
pr
io
r
to
sl
ee
p
ap
ne
a
14
%
of
pa
tie
nt
s
ha
d
di
ag
no
si
s
of
de
pr
es
si
on
.F
em
al
e
OS
AS
pa
tie
nt
s
w
er
e
m
or
e
th
an
tw
ic
e
as
lik
el
y
as
m
al
e
pa
tie
nt
s
to
ha
ve
di
ag
no
si
s
of
de
pr
es
si
on
Ba
rd
w
el
le
t
al
.(
35
)
(a
)6
4
(b
)5
4
M
;1
0
F
(c
)4
9
(8
)
(d
)R
DI
:5
2
(2
9)
CE
S-
D
(ra
ng
e:
0–
60
)
PO
M
S*
33
%
of
pa
tie
nt
s
ha
d
m
oo
d
di
so
rd
er
ba
se
d
on
CE
S-
D
30
%
of
pa
tie
nt
s
ha
d
de
pr
es
si
ve
st
at
e
ba
se
d
on
PO
M
S
Ba
rd
w
el
le
t
al
.(
33
)
(a
)6
7
(o
f
w
hi
ch
45
ha
d
lo
w
sc
or
e
in
CE
S-
D
an
d
22
ha
d
hi
gh
sc
or
e
in
CE
S-
D)
(b
)5
7
M
;1
0
F
(c
)4
9.
3
(n
ot
re
po
rte
d)
(d
)R
DI
:5
1
(2
9)
CE
S-
D
(ra
ng
e:
0–
60
)
33
%
of
pa
tie
nt
s
ha
d
dy
st
hy
m
ia
or
m
aj
or
de
pr
es
si
on
.
CE
S-
D
m
ea
n
sc
or
e
(S
D)
fo
r
hi
gh
sc
or
e
pa
tie
nt
s
w
as
25
.0
(7
.2
)a
nd
fo
r
lo
w
sc
or
e
pa
tie
nt
s
6.
2
(4
.2
)
Da
hl
çf
et
al
.(
59
)
(a
)5
3
(b
)5
3
M
(c
)5
0
(9
)
(d
)A
HI
:5
6
(2
4)
CP
RS
*
St
ru
ct
ur
ed
Cl
in
ic
al
In
te
rv
ie
w
fo
r
DS
M
-II
I-R
34
%
of
pa
tie
nt
s
ha
d
de
pr
es
si
ve
ep
is
od
es
:2
3%
ha
d
m
aj
or
de
pr
es
si
on
,9
%
dy
st
hy
m
ia
,a
nd
2%
a
de
pr
es
si
ve
di
so
rd
er
no
t
ot
he
rw
is
e
sp
ec
ifi
ed
.O
ne
pa
tie
nt
ha
d
a
ge
ne
ra
liz
ed
an
xi
et
y
di
so
rd
er
Saunama¨ki & Jehkonen
6
T
a
b
le
3
(C
on
tin
ue
d)
Re
fe
re
nc
e
Pa
tie
nt
ch
ar
ac
te
ris
tic
s:
(a
)N
um
be
r
of
su
bj
ec
ts
(b
)G
en
de
r
(c
)A
ge
(y
ea
rs
):
m
ea
n
(S
D)
(d
)S
ev
er
ity
of
OS
AS
:m
ea
n
(S
D)
M
oo
d
sc
al
e
(s
co
rin
g:
ra
ng
e)
Pr
ev
al
en
ce
of
de
pr
es
si
on
an
d
an
xi
et
y
Ya
m
am
ot
o
et
al
.(
34
)
(a
)4
1
(b
)4
1
M
(c
)N
ot
re
po
rte
d
d)
AH
I:
se
ve
re
Zu
ng
SD
S
(ra
ng
e:
25
–1
00
)
63
%
ha
d
sc
or
e
in
di
ca
tin
g
de
pr
es
si
ve
st
at
e.
Zu
ng
SD
S
m
ea
n
sc
or
e
(S
D)
fo
r
th
e
pa
tie
nt
gr
ou
p
w
as
42
.9
(7
.8
)
Ai
ke
ns
et
al
.(
28
)
(a
)3
0
(b
)N
ot
re
po
rte
d
(c
)N
ot
re
po
rte
d
(d
)A
HI
:5
8
(4
6)
M
M
PI
*
De
pr
es
si
on
su
bs
ca
le
of
th
e
M
M
PI
w
as
el
ev
at
ed
in
25
%
of
th
e
pa
tie
nt
s
Ai
ke
ns
et
al
.(
25
)
(a
)1
78
(b
)1
55
M
;2
3
F
(c
)4
8
(1
1)
(d
)A
HI
:5
9
(3
7)
M
M
PI
*
De
pr
es
si
on
su
bs
ca
le
of
th
e
M
M
PI
w
as
el
ev
at
ed
in
32
%
of
th
e
pa
tie
nt
s
Ai
ke
ns
et
al
.(
26
)
(a
)4
9
(b
)N
ot
re
po
rte
d
(c
)N
ot
re
po
rte
d
(d
)A
HI
:5
5
(3
7)
M
M
PI
*
De
pr
es
si
on
su
bs
ca
le
of
th
e
M
M
PI
w
as
el
ev
at
ed
in
49
%
of
th
e
pa
tie
nt
s
Ai
ke
ns
et
al
.(
27
)
(a
)1
1
(b
)N
ot
re
po
rte
d
(c
)5
5
(1
2)
(d
)A
HI
:2
0
(1
5)
SC
L-
90
*
46
%
of
OS
AS
pa
tie
nt
s
co
ul
d
be
cl
as
si
fie
d
w
ith
a
pr
ob
ab
le
ps
yc
hi
at
ric
di
so
rd
er
.D
ep
re
ss
io
n
su
bs
ca
le
w
as
el
ev
at
ed
in
36
%
of
th
e
pa
tie
nt
s
an
d
an
xi
et
y
su
bs
ca
le
w
as
el
ev
at
ed
in
27
%
of
th
e
pa
tie
nt
s
En
gl
em
an
et
al
.(
30
)
(a
)3
4
(b
)2
1
M
;1
3
F
(c
)4
4
(8
)
(d
)A
HI
:1
0
(3
)
HA
DS
(ra
ng
e:
de
pr
es
si
on
su
bs
ca
le
:
0–
21
;a
nx
ie
ty
su
bs
ca
le
:0
–2
1)
41
%
of
th
e
pa
tie
nt
s
ha
d
de
pr
es
si
ve
st
at
e
an
d
67
%
of
th
e
pa
tie
nt
s
ha
d
an
xi
et
y
HA
DS
de
pr
es
si
on
m
ea
n
sc
or
e
(S
D)
fo
r
th
e
pa
tie
nt
gr
ou
p
w
as
7.
4
(4
.1
).
HA
DS
an
xi
et
y
m
ea
n
sc
or
e
(S
D)
fo
r
th
e
pa
tie
nt
gr
ou
p
w
as
9.
0
(4
.2
)
N
am
bu
et
al
.(
31
)
(a
)2
0
(b
)1
2
M
;8
F
(c
)5
1
(1
0)
(d
)A
I:
19
(1
5.
6)
;a
pn
ei
c
ep
is
od
es
⁄n
ig
ht
16
7
(1
31
)
ST
AI
(ra
ng
e:
no
t
re
po
rte
d)
SD
S
(ra
ng
e:
no
t
re
po
rte
d)
47
%
of
th
e
pa
tie
nt
s
ha
d
de
pr
es
si
ve
st
at
e:
21
%
ha
d
m
ild
de
pr
es
si
on
an
d
26
%
m
od
er
at
e
de
pr
es
si
on
.
St
at
e
an
xi
et
y
w
as
ab
ov
e
no
rm
al
lim
its
in
63
%
of
th
e
pa
tie
nt
s,
an
d
tra
it
an
xi
et
y
w
as
ab
ov
e
no
rm
al
lim
its
in
47
%
of
th
e
pa
tie
nt
s.
SD
S
m
ea
n
sc
or
e
(S
D)
fo
r
th
e
pa
tie
nt
gr
ou
p
w
as
39
.2
(1
1.
0)
.S
TA
I
st
at
e
an
xi
et
y
m
ea
n
sc
or
e
(S
D)
fo
r
th
e
pa
tie
nt
gr
ou
p
w
as
44
.6
(1
2.
1)
.S
TA
It
ra
it
an
xi
et
y
m
ea
n
sc
or
e
(S
D)
fo
r
th
e
pa
tie
nt
gr
ou
p
w
as
46
.2
(1
3.
4)
Bo
ra
k
et
al
.(
21
)
(a
)2
0
(b
)2
0
M
(c
)4
6
(6
)
(d
)A
HI
:6
7
(1
6)
BD
I
(ra
ng
e:
0–
63
)
M
AS
*
55
%
of
th
e
pa
tie
nt
s
pr
es
en
te
d
w
ith
de
pr
es
si
ve
sy
m
pt
om
s.
70
%
of
th
e
pa
tie
nt
s
pr
es
en
te
d
w
ith
an
xi
et
y.
BD
Im
ea
n
sc
or
e
(S
D)
fo
r
th
e
pa
tie
nt
gr
ou
p
w
as
7.
5
(7
.8
).
M
AS
m
ea
n
sc
or
e
(S
D)
fo
r
th
e
pa
tie
nt
gr
ou
p
w
as
55
.3
(1
5.
8)
M
,m
en
;F
,f
em
al
e;
SD
,s
ta
nd
ar
d
de
vi
at
io
n;
AH
I,
ap
ne
a
hy
po
pn
ea
in
de
x;
RD
I,
re
sp
ira
to
ry
di
st
ur
ba
nc
e
in
de
x;
AI
,a
pn
ea
in
de
x;
BD
I,
Be
ck
De
pr
es
si
on
In
ve
nt
or
y;
CE
S-
D,
Ce
nt
er
fo
r
Ep
id
em
io
lo
gi
ca
lS
tu
di
es
De
pr
es
si
on
Sc
al
e;
Zu
ng
SD
S,
Zu
ng
Se
lf-
Ra
tin
g
De
pr
es
si
on
Sc
al
e;
HA
DS
,H
os
pi
ta
lA
nx
ie
ty
an
d
De
pr
es
si
on
Sc
al
e;
PO
M
S,
Pr
of
ile
of
M
oo
d
St
at
es
;S
CL
-9
0,
Sy
m
pt
om
Di
st
re
ss
Ch
ec
k
Li
st
;S
TA
I,
St
at
e-
Tr
ai
tA
nx
ie
ty
In
ve
nt
or
y;
CP
RS
,C
om
pr
eh
en
si
ve
Ps
yc
ho
pa
th
ol
og
ic
al
Ra
tin
g
Sc
al
e;
M
M
PI
,
M
in
ne
so
ta
M
ul
tip
ha
si
c
Pe
rs
on
al
ity
In
ve
nt
or
y;
SD
S,
Se
lf-
Ra
tin
g
De
pr
es
si
on
Sc
al
e;
M
AS
,T
ay
lo
rs
M
an
ife
st
An
xi
et
y
Sc
al
e.
*P
OM
S,
SC
L-
90
,a
nd
M
M
PI
ar
e
sc
al
es
w
hi
ch
al
so
ev
al
ua
te
as
pe
ct
s
of
m
oo
d
ot
he
rt
ha
n
de
pr
es
si
on
an
d
an
xi
et
y,
an
d
th
er
ef
or
e
no
ex
ac
tr
an
ge
fo
rt
he
se
sc
al
es
is
re
po
rte
d.
So
m
e
ot
he
rr
ar
el
y
us
ed
sc
al
es
(C
PR
S,
M
AS
)d
id
no
tr
ep
or
tt
he
ra
ng
e
fo
r
de
pr
es
si
on
an
d
an
xi
et
y
sc
al
es
ei
th
er
.
Depression and anxiety in OSAS
7
purposes of evaluating the prevalence of depression
and anxiety. The mean age of the patients ranged
from 44 to 69 years. Age may play a role in the
appearance of mood disorders; among women in
particular, depressive symptoms are more common
inmenopausal age. Although the proportion ofmen
varied widely (13–100%), themajority of the studies
consisted mainly of men (median: 83%). The
imbalance in the distribution of genders may signi-
ﬁcantly aﬀect the results for the prevalence of
depression: it has been reported that women with
OSAS may have more depressive symptoms than
men (40, 54, 58, 68), although conﬂicting results
have also been reported (69). The estimated preval-
ence of depressionwould probably have been higher
had the study samples been gender-balanced.
According to Pillar and Lavie (58), the differences
between men and women in mood alterations arise
from basic differences in gender personality charac-
teristic and are unrelated to OSAS.
The mean severity of OSAS in the studies
reviewed varied from mild to severe. Most studies
consisted of heterogeneous patient groups inclu-
ding patients with mild to severe sleep apnea or
patients with moderate to severe sleep apnea. Most
of the reported prevalence ﬁgures for depression or
anxiety were from studies with heterogeneous
study groups in terms of OSAS severity. In an
analysis of the few homogeneous patient groups,
the mean severity of OSAS did not seem to
correlate linearly with the prevalence of depression.
Even in those studies (30, 38) that focused on
patients with mild OSAS, the reported prevalence
of depression varied from 16% to 41%. The
prevalence of anxiety was also high (67%) in the
study by Engleman et al. (30), although OSAS
severity was mild.
Depression and anxiety were mostly evaluated
with the BDI, HADS, POMS, CES-D, Zung SDS,
MMPI and SCL-90, and their diﬀerent versions
(particularly the BDI). POMS, MMPI, and
SCL-90 also include assessments of psychological
conditions other than depression and anxiety.
Comparison between the studies was diﬃcult
because the cut-oﬀ scores varied for the same
mood scale or no cut-oﬀ score was deﬁned. In three
studies the evaluation of depression was based on
the Structured Clinical Interview for DSM-IV,
DSM-III-R or DSM-III. A few other studies used
psychiatric interviews but did not report their
results in any detail. The diagnosis of depression or
anxiety cannot be based on the mood scales only,
without a structured psychiatric interview follow-
ing the international criteria of DSM-IV or ICD-
10. It follows that most of the studies reviewed do
not evaluate depression or anxiety as a clinical
entity, but instead report symptoms of depression
or anxiety on the basis of diﬀerent scales, such as
the BDI or HADS. In addition, the most reliable
ﬁgures for the prevalence of depression and anxiety
as clinical entities are provided by studies using
psychiatric evaluation based on international
criteria, while results for the prevalence of depres-
sive and anxious symptoms can be drawn from
studies using mood scales. The studies reviewed
showed a marked variety in the prevalence of both
Table 4 Main results on the effect of CPAP treatment (treatment time ‡3 months) on depression and anxiety in patients with obstructive sleep apnea syndrome
Reference Mood scale
CPAP:
(a) Treatment time
(b) Compliance Main results
Barnes et al. (47) BDI
POMS
(a) 3 months
(b) 3.6 h ⁄ night
BDI scores did not decline with CPAP over placebo-treatment.
Total POMS score declined more with CPAP than with placebo treatment
Means et al. (45) BDI (a) 3 months
(b) 4.3 h ⁄ night
Significant decline in depression. Somatic symptoms of depression
did not improve more than affective ⁄ cognitive symptoms
Snchez et al. (36) BDI
STAI
(a) 1 and 3 months
(b) 5.5 h and 5.8 h ⁄ night
Significant decline in depression after 1 and 3 months treatment.
State of anxiety did not decline after 1 month, but declined
after 3 months of treatment. Trait anxiety declined at both time-points.
Improvement in emotional stability can also be explained with
overall improvement in quality of life
Kingshott et al. (60) HADS (a) 6 months
(b) 4.8 h ⁄ night
Significant decline was found both in depression and in anxiety.
Munoz et al. (61) Beck tests (a) 3 and 12 months
(b) 5.8 h ⁄ night
No significant decline in depression or anxiety
Yamamoto et al. (34) Zung SDS (a) 2 years
(b) 97.8%
Significant decline in depression. Half of the patients who had depressive
state at baseline improved to the normal level
Borak et al. (21) BDI
MAS
(a) 3 and 12 months
(b) Not reported
No improvement in emotional status
CPAP, continuous positive airway pressure treatment; BDI, Beck Depression Inventory; POMS, Profile of Mood States; STAI, State-Trait Anxiety Inventory; HADS, Hospital
Anxiety and Depression Scale; Zung SDS, Zung Self-Rating Depression Scale; MAS, Taylors Manifest Anxiety Scale.
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depression (7–63%) and anxiety (11–70%). When
reported, the severity of depression was usually
rated as mild. Prevalence ﬁgures for depression and
anxiety varied widely, even between studies using
the same method of assessment: for example, the
prevalence of depressive symptoms based on
diﬀerent versions of BDI ranged from 16% to
55% (21, 38, 45, 47, 65, 69, 75). Nevertheless,
mood scales may well be adequate for assessing
mood in OSAS patients if the depressive and
anxious state is seen as secondary to the medical
disorder, and if the mood disorders are improved
with the treatment. A psychiatric consultation is
necessary if the treatment of OSAS does not result
in mood improvement.
There is no clear consensus between the compli-
ance and the treatment time of CPAP and the
eﬀectiveness of treatment. Stepnowsky and Moore
(95) stated in their review that longer CPAP use
leads to better treatment outcome. In the studies
reviewed, compliance ranged from 3.1 to 7.0 h per
night and the treatment time ranged from 1 week
to 2 years (median: 8 weeks). The compliance time
less than 4 h per night and the treatment time less
than 3 months might be too short to have any
effects on mood. Therefore, we focused to clarify
the effect of CPAP treatment on mood in the
studies with the treatment time at least 3 months.
Depressive symptoms declined in four out of seven
studies and anxiety in two out of four studies.
Thus, the results of the effect of CPAP treatment
on mood are not conclusive.
According to Means et al. (45) persisting mood
disorder conﬁrms that OSAS also involves a mood
component. Furthermore, Mun˜oz et al. (61) also
pointed out that anxious and depressive symptoms
may develop despite effective treatment because of
chronic CPAP use and awareness that the treat-
ment is only symptomatic, not curative. Further-
more, patients behavioral and personality
characteristics (e.g., choice of coping strategies)
may have a major inﬂuence on which OSAS
patients will experience greater disturbance of
mood (35).
One limitation of this review is that it does not
extend to correlations between mood disorders and
nocturnal sleep variables. Earlier studies report
diﬀering results on these correlations, but a
systematic analysis of these relationships could
make intelligible the overall relationship between
mood alterations and OSAS as well as the impact
of CPAP treatment on mood. Secondly, the focus
of our review was conﬁned to the most common
mood alterations in OSAS, namely depression and
anxiety. However, other less common psychiatric
states in OSAS have been linked to somatization,
obsession-compulsion, hostility, chronic dyspho-
ria, somatic concern, nocturnal panic attacks, and
psychotic episodes (6, 7, 10). A third limitation is
that we excluded studies that concentrated on
quality of life, yet some methods for assessing
quality of life may involve mood aspects as well.
The main focus of our ongoing study is on
executive dysfunction in OSAS (96) as well as on
the assessment of mood disorders and quality of
life. On the basis of this review and the preliminary
ﬁndings of our ongoing study, some recommenda-
tions for further research can be offered. First,
more careful attention should be paid to the
background variables of subject selection. The
age and gender of subjects may have a signiﬁcant
impact on mood results; women in postmenopau-
sal age and women overall are more vulnerable to
mood alterations. Secondly, it is important to take
note of the limitations of mood scales, which are
not proper diagnostic tools for the detection of
depression or anxiety; they only represent depres-
sive and anxious symptoms. Diagnosis of the
clinical entity requires a psychiatric consultation.
Thirdly, before any treatment is initiated for mood
disorders, it is necessary to establish whether OSAS
lies behind depressive symptoms in middle-aged,
obese patients with sleep problems as Kaplan (9)
has recommended. Fourthly, the evaluation of
mood is essential when the clinical assessment or
research focuses on the cognitive effects of OSAS,
because mood disorders may be indicative of some
deﬁcits in cognitive processing.
In conclusion, the wide variance in the preval-
ence of depression and anxiety may be due to
diﬀerent reasons: study selection, patient charac-
teristics (gender, age, personal diﬀerences), the
methods used to assess depression and anxiety,
and the overlap between mood alteration and
OSAS-related symptoms. In many cases it seems
that depression and anxiety are secondary to the
medical disorder, but it is possible that a primary
emotional component is also involved in the
mood alterations seen in OSAS patients. CPAP
may improve depressive and anxious symptoms
but there are only a few long-term follow-up
studies concerning the eﬀectiveness of CPAP on
mood.
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